Weekly CFO Buys Highlight
According to GuruFocus Insider Data, the recent Chief Financial Officer (CFO) buys were for RCM Technologies Inc. (NASDAQ:RCMT), Digirad Corp (NASDAQ:DRAD) and Cellectar Biosciences Inc. (CLRB).
RCM Technologies Inc. CFO Kevin D. Miller bought 150,000 shares
CFO Kevin D. Miller bought 150,000 shares for $1.20 per share on June 2. Since then, the stock price has increased by 62.5%. RCM Technologies Inc. has a market cap of $22.04 million and its shares were traded around $1.95. The company has a price-sales ratio of 0.14.
RCM Technologies Inc. announced its first-quarter results with revenue of $45.03 million and gross profit of $10.84 million, while the net loss was $5.95 million. The 2019 total revenue was $191.10 million, a 0.5% decrease from 2018. The gross profit was $48.59 million, a 1% decrease from the year prior. The net loss was $4.06 million.
Director Roger H. Ballou bought 100,000 shares for $1.20 per share on June 2. Since then, the stock price has increased by 62.5%.
Bradley Vizi bought 850,000 shares for $1.20 per share on June 2. Since then, the stock price has increased by 62.5%.
Digirad Corp Chief Operating Officer and CFO David J. Noble bought 20,000 shares
Chief Operating Officer and CFO David J. Noble bought 20,000 shares for $2.24 per share on May 28. Since then, the stock price has increased by 34.82%. Digirad Corp has a market cap of $13.060 million and its shares were traded around $3.02. The company has a price-sales ratio of 0.05.
Digirad Corp announced its first-quarter results with revenue of $28.86 million and gross profit of $4.44 million, while the net loss was $2.95 million. The 2019 total revenue was $114.19 million, a 10% increase from 2018. The gross profit was $22.12 million, a 7% increase from the year prior. The net loss was $4.63 million.
President and CEO Matthew G. Molchan bought 2,000 shares for $2.24 per share on May 28. Since then, the stock price has increased by 34.82%.
Director Jeffrey E. Eberwein bought 44,000 shares for $2.24 per share on May 28. Since then, the stock price has increased by 34.82%.
Director Michael A. Cunnion bought 5,000 shares for $2.24 per share on May 28. Since then, the stock price has increased by 34.82%.
Director Mitchell I Quain bought 22,000 shares for $2.24 per share on May 28. Since then, the stock price has increased by 34.82%.
Cellectar Biosciences Inc. CFO Dov Elefant bought 4,348 shares
CFO Dov Elefant bought 4,348 shares for $1.15 per share on June 5. Since then, the stock price has increased by 2.61%. Cellectar Biosciences Inc. has a market cap of $11.080 million and its shares were traded around $1.18. Over the past 10 years, Cellectar Biosciences Inc. had an annual average earnings growth of 57.00%.
President and CEO James V. Caruso bought 21,740 shares for $1.15 per share on June 5. Since then, the stock price has increased by 2.61%.
Chief Business Officer Jarrod Longcor bought 65,218 shares for $1.15 per share on June 5. Since then, the stock price has increased by 2.61%.
Director Stephen A. Hill bought 18,000 shares for $1.08 per share on June 4. Since then, the stock price has increased by 9.26%.
Disclosure: none
Not a Premium Member of GuruFocus? Sign up for a free 7-day trial here.
This article first appeared on GuruFocus.
